CNSP — CNS Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $2.59m
- $2.34m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | -1018.78% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system (CNS). The Company's lead drug candidate, Berubicin, is a novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier. Berubicin is in development for the treatment of a number of serious brain and CNS oncology indications, including glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. In addition, the Company is advancing the development of its WP1244/WP1874 drug technology, which utilizes anthracycline and distamycin-based scaffolds to create small molecule agents. The Company is also evaluating the use of WP1244/WP1874 in the treatment of other primary brain and central nervous system cancers, as well as cancers metastatic to the brain including pancreatic, ovarian, and lymphomas.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 27th, 2017
- Public Since
- November 8th, 2019
- No. of Shareholders
- 11,500
- No. of Employees
- 3
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 10,634,932
- Address
- 2100 West Loop S Ste 900, HOUSTON, 77027-3522
- Web
- https://cnspharma.com/
- Phone
- Contact
- Jenene Thomas
- Auditors
- Malone Bailey, LLP
Upcoming Events for CNSP
Q1 2024 CNS Pharmaceuticals Inc Earnings Release
Q2 2024 CNS Pharmaceuticals Inc Earnings Release
CNS Pharmaceuticals Inc Annual Shareholders Meeting
Similar to CNSP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the CNS Pharmaceuticals share price?
As of Today at 19:05 UTC, shares in CNS Pharmaceuticals are trading at $0.24. This share price information is delayed by 15 minutes.
How has the CNS Pharmaceuticals share price performed this year?
Shares in CNS Pharmaceuticals last closed at $0.24 and the price had moved by -64.47% over the past 365 days. In terms of relative price strength the CNS Pharmaceuticals share price has underperformed the S&P500 Index by -71.3% over the past year.
What are the analyst and broker recommendations for CNS Pharmaceuticals?
The overall consensus recommendation for CNS Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the CNS Pharmaceuticals dividend yield?
CNS Pharmaceuticals does not currently pay a dividend.
Does CNS Pharmaceuticals pay a dividend?
CNS Pharmaceuticals does not currently pay a dividend.
When does CNS Pharmaceuticals next pay dividends?
CNS Pharmaceuticals does not currently pay a dividend.
How do I buy CNS Pharmaceuticals shares?
To buy shares in CNS Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of CNS Pharmaceuticals?
As of the previous close price of $0.24, shares in CNS Pharmaceuticals had a market capitalisation of $2.59m.
Where are CNS Pharmaceuticals shares listed?
Here are the trading details for CNS Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: CNSP
What kind of share is CNS Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum CNS Pharmaceuticals is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a CNS Pharmaceuticals share price forecast for 2024?
We could not find analyst target price data for this security.
What is the trend in the CNS Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CNS Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -84.61%.
As of the last closing price of $0.24, shares in CNS Pharmaceuticals were trading -81.48% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the CNS Pharmaceuticals PE Ratio?
The CNS Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.24.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of CNS Pharmaceuticals?
We do not have data on CNS Pharmaceuticals' directors